Miyawaki Daisuke, Murakami Masao, Demizu Yusuke, Sasaki Ryohei, Niwa Yasue, Terashima Kazuki, Nishimura Hideki, Hishikawa Yoshio, Sugimura Kazuro
Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan.
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):378-84. doi: 10.1016/j.ijrobp.2008.12.092.
To assess the incidence of early delayed or late morbidity of the brain after particle therapy for skull base tumors and head-and-neck cancers.
Between May 2001 and December 2005, 59 patients with cancerous invasion of the skull base were treated with proton or carbon ion therapy at the Hyogo Ion Beam Medical Center. Adverse events were assessed according to the magnetic resonance imaging findings (late effects of normal tissue-subjective, objective, management, analytic [LENT-SOMA]) and symptoms (Common Terminology Criteria for Adverse Events [CTCAE], version 3.0). Dose-volume histograms were used to analyze the relationship between the dose and volume of the irradiated brain and the occurrence of brain injury. The median follow-up time was 33 months.
Of the 48 patients treated with proton therapy and 11 patients treated with carbon ion radiotherapy, 8 (17%) and 7 (64%), respectively, developed radiation-induced brain changes (RIBCs) on magnetic resonance imaging (LENT-SOMA Grade 1-3). Four patients (7%) had some clinical symptoms, such as vertigo and headache (CTCAE Grade 2) or epilepsy (CTCAE Grade 3). The actuarial occurrence rate of RIBCs at 2 and 3 years was 20% and 39%, respectively, with a significant difference in the incidence between the proton and carbon ion radiotherapy groups. The dose-volume histogram analyses revealed significant differences between the brain lobes with and without RIBCs in the actuarial volume of brain lobes receiving high doses.
Particle therapies produced minimal symptomatic brain toxicities, but sequential evaluation with magnetic resonance imaging detected a greater incidence of RIBCs. Significant differences were observed in the irradiated brain volume between the brain lobes with and without RIBCs.
评估质子治疗颅底肿瘤和头颈癌后脑早期延迟或晚期发病的发生率。
2001年5月至2005年12月期间,59例颅底癌侵犯患者在兵库离子束医学中心接受了质子或碳离子治疗。根据磁共振成像结果(正常组织晚期效应——主观、客观、管理、分析[LENT-SOMA])和症状(不良事件通用术语标准[CTCAE],第3.0版)评估不良事件。使用剂量体积直方图分析照射脑的剂量和体积与脑损伤发生之间的关系。中位随访时间为33个月。
在48例接受质子治疗的患者和11例接受碳离子放疗的患者中,分别有8例(17%)和7例(64%)在磁共振成像上出现放射性脑改变(RIBCs)(LENT-SOMA 1-3级)。4例患者(7%)出现了一些临床症状,如眩晕和头痛(CTCAE 2级)或癫痫(CTCAE 3级)。RIBCs在2年和3年时的精算发生率分别为20%和39%,质子和碳离子放疗组之间的发生率存在显著差异。剂量体积直方图分析显示,有和没有RIBCs的脑叶在接受高剂量的脑叶精算体积方面存在显著差异。
粒子治疗产生的有症状脑毒性极小,但通过磁共振成像进行的连续评估检测到RIBCs的发生率更高。在有和没有RIBCs的脑叶之间,照射脑体积存在显著差异。